Patients who take blockbuster drugs like Wegovy or Ozempic for weight loss may face life-threatening complications if they need surgery or other procedures that require empty stomachs for anesthesia. This summer's guidance to halt the medication for up...
Some anesthesiologists in the U.S. and Canada say they’ve seen growing numbers of patients on the weight-loss drugs who inhaled food and liquid into their lungs while sedated because their stomachs were still full - even after following standard instructions to stop eating for six to eight hours in advance.
It’s not clear how many patients taking the anti-obesity drugs may be affected by the issue. But because the consequences can be so dire, Hobai and a group of colleagues decided to speak out. Writing in the Canadian Journal of Anesthesia, they called for the drug to be stopped for even longer - about three weeks before sedation.
Champeau and Jones both acknowledged there’s not enough evidence to say for certain how long semaglutide should be held to make anesthesia safe. Many patients won’t see providers far enough in advance to stop the drug three weeks before procedures, Champeau noted. Since then, doctors have seen dozens of similar cases as use of the weight-loss medication has grown, said Dr. Elisa Lund, an anesthesiologist at the University of North Carolina at Chapel Hill School of Medicine. “It has exponentially increased,” she said.
Novo Nordisk, which makes Ozempic, Wegovy and similar drugs, said the firm’s clinical trial and post-marketing safety data did not show that the medications led to aspiration. But the drugmaker noted that the medications are known to cause delayed emptying of the stomach and that the labels warn of possible gastrointestinal side effects.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Can Ozempic and Wegovy cause 'stomach paralysis' and 'cyclic vomiting'?Recent reports have raised concerns about the potential side effects of GLP-1 receptor agonist drugs, such as Ozempic and Wegovy, including persistent vomiting and 'stomach paralysis'.
Weiterlesen »
Wegovy patients see 20% reduction in cardiovascular risksPatients taking the new weight-loss drug, Wegovy, experienced a significant drop in the risk of heart attack, stroke, and cardiovascular death over a five-year period. These results exceeded expectations, with a 20% reduction in heart attacks and stroke, which has not been seen before with any approved weight loss medication.
Weiterlesen »
Wegovy patients saw 20% reduction in cardiovascular risks, drugmaker saysWegovy, one of a new class of drugs used for weight loss, reduced the risk of heart attacks in overweight adults in a large trial, according to its manufacturer.
Weiterlesen »
Wagovy, Ozempic patients could face higher risk of complications under anesthesiaDrugs like Wegovy and Ozempic can slow digestion so much that it puts patients at increased risk for pulmonary aspiration when they're under anesthesia.
Weiterlesen »
Nearly half of Americans interested in weight-loss drugs like Wegovy, survey findsA KFF health tracking poll found 45% of people are interested in taking a safe and effective weight loss medication
Weiterlesen »